Patents by Inventor Donald E. Bierer

Donald E. Bierer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER
    Publication number: 20110195110
    Abstract: Pyrazole urea compounds, pharmaceutical compositions which contain them and methods for treating cancer using them.
    Type: Application
    Filed: December 1, 2006
    Publication date: August 11, 2011
    Inventors: Roger Smith, Holia N. Hatoum-Mokdad, Louis David Cantin, Donald E. Bierer, Wenlang Fu, Dhanapalan Nagarathnam, Gaetan Ladouceur, Yamin Wang, Herbert Ogutu, Scot Wilhelm, Ian Taylor, Sanjeeva Reddy, Richard Gedrich, Christopher Carter, Aaron Schmitt, Xiaomei Zhang
  • 4-AMINO-5,6-SUBSTITUTED THIOPHENO [2,3-D] PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND THEIR USE IN THE TREATMENT OR PREVENTION OF PDE7B-MEDIATED DISEASES AND CONDITIONS
    Patent number: 6849638
    Abstract: The invention relates to 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same and their use to treat or prevent diseases and conditions mediated by the phosphodiesterase enzyme 7B (PDE7B). Diseases and conditions mediated by PDE7B include osteoporosis, osteopenia and asthma.
    Type: Grant
    Filed: April 29, 2002
    Date of Patent: February 1, 2005
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Andreas Stolle, Donald E. Bierer, Yuanwei Chen, Dongping Fan, Barry Hart, Mary Katherine Monahan, William J. Scott
  • 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
    Publication number: 20040267017
    Abstract: The invention provides novel thiazoles bearing 3-pyridyl or 4-isoquinilinyl substituents, and pharmaceutical compositions thereof. The invention also provides methods of using compounds of the invention and pharmaceutical compositions thereof as inhibitors of lyases, e.g., the 17a-hydroxylase-C17,20 enzyme. The invention further provides methods for treating cancer in a subject, comprising administering to the subject a compound of the invention or a pharmaceutical composition thereof. The cancer can be, e.g., prostate cancer or breast cancer.
    Type: Application
    Filed: March 26, 2004
    Publication date: December 30, 2004
    Inventors: Donald E Bierer, Jeffrey Johnson, Gaetan Ladouceur, William J Scott, Andrea C McClure, Wenlang Fu, Furahi Achebe, Michael Burke, Chen Bi, Barry P Hart
  • Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
    Publication number: 20040236110
    Abstract: The invention provides novel substituted 3-pyridyl indoles and indazoles and pharmaceutical compositions thereof. The invention also provides methods of use of substituted 3-pyridyl indoles and indazoles and pharmaceutical compositions thereof as inhibitors of lyases, e.g., the 17&agr;-hydroxylase-C17,20-lyase enzyme. The invention further provides methods for the treatment of cancer in a subject, comprising administering a substituted 3-pyridyl indoles and indazoles or a pharmaceutical composition comprising a substituted 3-pyridyl indoles and indazoles to a subject. The cancer can be, e.g., prostate cancer or breast cancer.
    Type: Application
    Filed: March 26, 2004
    Publication date: November 25, 2004
    Inventors: Gaetan H Ladouceur, Michael Burke, Wai C Wong, Donald E Bierer
  • Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors
    Publication number: 20040209924
    Abstract: This invention provides 3-pyridyl imidazoles, pharmaceutical compositions containing them, and methods of using these for treatment of cancer.
    Type: Application
    Filed: March 26, 2004
    Publication date: October 21, 2004
    Inventors: Barry Hart, Donald E Bierer, Jacques Dumas, Robert Sibley, Chengzhi Zhang
  • Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
    Publication number: 20040198773
    Abstract: Substituted 3-pyridyl oxazoles which inhibit C17, 20 Lyase, pharmaceutical preparations containing them, and methods of using them in treatment of cancer arc provided.
    Type: Application
    Filed: March 26, 2004
    Publication date: October 7, 2004
    Inventors: Barry Hart, Donald E Bierer, Chengzhi Zhang
  • 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of PDE7B-mediated diseases and conditions
    Publication number: 20030119829
    Abstract: The invention relates to 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same and their use to treat or prevent diseases and conditions mediated by the phosphodiesterase enzyme 7B (PDE7B). Diseases and conditions mediated by PDE7B include osteoporosis, osteopenia and asthma.
    Type: Application
    Filed: April 29, 2002
    Publication date: June 26, 2003
    Inventors: Andreas Stolle, Donald E. Bierer, Yuanwei Chen, Dongping Fan Can, Barry Hart, Mary Katherine Monahan, William J. Scott
  • Methods for use of cryptolepine analogs with hypoglycemic activity
    Patent number: 5925647
    Abstract: Novel cryptolepine analogs useful as hypoglycemic agents and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes, and a method for their synthesis are described. As hypoglycemic agents, the novel cryptolepine analogs are useful for the treatment of insulin-dependent diabetes mellitus (IDDM or Type I) and non-insulin dependent diabetes mellitus (NIDDM or Type II).
    Type: Grant
    Filed: October 20, 1997
    Date of Patent: July 20, 1999
    Assignee: Shaman Pharmaceuticals, Inc.
    Inventor: Donald E. Bierer
  • Hypoglycemic agent from cryptolepis
    Patent number: 5917052
    Abstract: The use of extracts from Cryptolepis sp. or quindoline alkaloids such quindoline and cryptolepine contained therein as hypoglycemic agents, as well as methods for obtaining the hypoglycemic agents are described. According to a preferred embodiment, the extracts are derived from Cryptolepis sanguinolenta. As hypoglycemic agents, the extracts or quindoline alkaloids such as quindoline or cryptolepine are useful for treating insulin-dependent (type I) and non-insulin-dependent (type II) diabetes.
    Type: Grant
    Filed: September 28, 1994
    Date of Patent: June 29, 1999
    Assignee: Shaman Pharmaceuticals, Inc.
    Inventors: Donald E. Bierer, Diana M. Fort
  • Process for the preparation of mono- and bis(phosphocholine) derivatives which have antifungal activity
    Patent number: 5811568
    Abstract: This invention pertains to a synthetic process for obtaining a unique phosphocholine derivative which has been isolated from the leaves of the plant Irbachia alata, identified to be 1,22-bis?2-(trimethylammonium)ethylphosphatyl! docosane is disclosed. Also disclosed is a synthetic process for obtaining a novel class of mono- and bis(phosphocholine) derivatives which are useful as antiinfective agents. The compounds are particularly effective in treating fungal infections, especially those caused by Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus.
    Type: Grant
    Filed: April 28, 1994
    Date of Patent: September 22, 1998
    Assignee: Shaman Pharmaceuticals, Inc.
    Inventors: Donald E. Bierer, Jeffrey M. Dener, Thien V. Truong
  • Hypoglycemic agent from cryptolepis
    Patent number: 5753790
    Abstract: The use of extracts from Cryptolepis sp. or quinodoline alkaloids such quindoline and cryptolepine contained therein as hypoglycemic agents, as well as methods for obtaining the hypoglycemic agents are described. According to a preferred embodiment, the extracts are derived from Cryptolepis sanguinolenta. As hypoglycemic agents, the extracts or quindoline alkaloids such as quindoline or cryptolepine are useful for treating insulin-dependent (type I) and non-insulin-dependent (type II) diabetes.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 19, 1998
    Assignee: Shaman Pharmaceuticals, Inc.
    Inventor: Donald E. Bierer
  • Aniline derivatives having antihyperglycemic activity
    Patent number: 5741926
    Abstract: Aniline derivatives useful as antihyperglycemic agents, pharmaceutical compositions comprising the aniline derivatives and methods for their use are described. The aniline derivatives are useful for the treatment of insulin-dependent diabetes mellitus (IDDM or Type I) and non-insulin dependent diabetes mellitus (NIDDM or Type II).
    Type: Grant
    Filed: February 12, 1997
    Date of Patent: April 21, 1998
    Assignee: Shaman Pharmaceuticals, Inc.
    Inventors: Donald E. Bierer, Larisa G. Dubenko
  • Class of phosphocholine derivatives having antifungal activity
    Patent number: 5681829
    Abstract: Certain phosphocholine derivatives having substantial antifungal therapeutic activity are disclosed. The phosphocholine derivatives may be chemically synthesized, enzymatically prepared or extracted from the plant Irlbachia alata. The phosphocholine derivatives are useful in treating fungal infections including those which are dermatophytic, systemic, ophthalmic and vaginal.
    Type: Grant
    Filed: April 5, 1995
    Date of Patent: October 28, 1997
    Assignee: Shaman Pharmaceuticals, Inc.
    Inventors: Michael Tempesta, Shivanand D. Jolad, Steven King, Guohua Mao, Reimar C. Bruening, John E. Kuo, Thien V. Troung, Donald E. Bierer, Jeffrey M. Dener
  • Cryptolepine analogs with hypoglycemic activity
    Patent number: 5681958
    Abstract: Novel cryptolepine analogs useful as hypoglycemic agents and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes, and a method for their synthesis are described. As hypoglycemic agents, the novel crytolepine analogs are useful for the treatment of insulin-dependent diabetes mellitus (IDDM or Type I) and non-insulin dependent diabetes mellitus (NIDDM or Type II).
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 28, 1997
    Assignee: Shaman Pharmaceuticals, Inc.
    Inventor: Donald E. Bierer
  • 1,2-dithiin antiinfective agents
    Patent number: 5668168
    Abstract: This invention pertains to a novel group of 1,2-dithiin compounds useful as antiinfective agents, and a novel synthetic process to produce the same. The compounds are particularly effective in treating fungal infections, especially those caused by Candida albicans, Cryptococcus neoformans or Aspergillus fumigatus.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 16, 1997
    Assignees: Shaman Pharmaceuticals, Inc., The Regents of the University of Michigan
    Inventors: Thien V. Truong, Donald E. Bierer, Jeffrey M. Dener, Richard Hector, Michael S. Tempesta, Bernard Loev, Wu Yang, Masato Koreeda
  • 1,2-dithiins having antifungal activity
    Patent number: 5648354
    Abstract: Novel 1,2-dithiin compounds useful as antifungal or anti-infective agents, as well as methods for their use as such, are described.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: July 15, 1997
    Assignee: Shaman Pharmaceuticals, Inc.
    Inventors: Donald E. Bierer, Jeffrey M. Dener, Joane Litvak, Larisa G. Dubenko
  • Hypoglycemic agent from cryptolepis
    Patent number: 5629319
    Abstract: The use of extracts from Cryptolepis sp. or quindoline alkaloids such quindoline and cryptolepine contained therein as hypoglycemic agents, as well as methods for obtaining the hypoglycemic agents are described. According to a preferred embodiment, the extracts are derived from Cryptolepis sanguinolenta. As hypoglycemic agents, the extracts or quindoline alkaloids such as quindoline or cryptolepine are useful for treating insulin-dependent (type I) and non-insulin-dependent (type II) diabetes.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 13, 1997
    Assignee: Shaman Pharmaceuticals, Inc.
    Inventors: Jian Luo, Diana M. Fort, Donald E. Bierer, Reimar C. Bruening
  • Hypoglycemic agent from cryptolepis
    Patent number: 5628999
    Abstract: The use of extracts from Cryptolepis sp. or quindoline alkaloids such quindoline and cryptolepine contained therein as hypoglycemic agents, as well as methods for obtaining the hypoglycemic agents are described. According to a preferred embodiment, the extracts are derived from Cryptolepis sanguinolenta. As hypoglycemic agents, the extracts or quindoline alkaloids such as quindoline or cryptolepine are useful for treating insulin-dependent (type I) and non-insulin-dependent (type II) diabetes.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 13, 1997
    Assignee: Shaman Pharmaceuticals, Inc.
    Inventors: Jian Luo, Diana M. Fort, Donald E. Bierer, Reimar C. Bruening, Steven R. King, Thomas J. Carlson
  • Preparation of symmetrical and unsymmetrical 3,6-disubstituted-1,2-dithiins having antifungal activity
    Patent number: 5583235
    Abstract: The present invention provides an improved procedure for the preparation of 3,6-disubstituted-1,2-dithiin derivatives, especially unsymmetrical 1,2-dithiins. In addition, the process offers significant process, scaleup, and safety advantages over the previously reported synthetic processes. The compounds synthesized by this new process and described herein are particularly effective in treating fungal infections, especially those caused by Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus, Trichophyton rubrum, Candida parapsilosis, Candida tropicalis, or Candida krusei.
    Type: Grant
    Filed: March 11, 1994
    Date of Patent: December 10, 1996
    Assignee: Shaman Pharmaceuticals, Inc.
    Inventors: Donald E. Bierer, Jeffrey M. Dener, Thien V. Truong
  • 1,2-dithiins having antifungal activity
    Patent number: 5580897
    Abstract: Novel 1,2-dithiin compounds useful as antifungal or anti-infective agents, as well as methods for their use as such, are described.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: December 3, 1996
    Assignee: Shaman Pharmaceuticals, Inc.
    Inventors: Donald E. Bierer, Patricia Peterli-Roth